D.E. Shaw & Co’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,921
| Closed | -$128K | – | 4905 |
|
|
2024
Q1 | $128K | Sell |
3,921
-158
| -4% | -$4.1K | ﹤0.01% | 3980 |
|
|
2023
Q4 | $109K | Buy |
+4,079
| New | +$169K | ﹤0.01% | 3964 |
|
|
2023
Q1 | – | Sell |
-643
| Closed | -$249K | – | 4954 |
|
|
2022
Q4 | $249K | Sell |
643
-615
| -49% | -$234K | ﹤0.01% | 4161 |
|
|
2022
Q3 | $424K | Buy |
1,258
+657
| +109% | +$238K | ﹤0.01% | 4128 |
|
|
2022
Q2 | $198K | Sell |
601
-953
| -61% | -$334K | ﹤0.01% | 4558 |
|
|
2022
Q1 | $680K | Buy |
+1,554
| New | +$638K | ﹤0.01% | 4182 |
|
|
2021
Q4 | – | Sell |
-614
| Closed | -$341K | – | 5770 |
|
|
2021
Q3 | $341K | Sell |
614
-2,448
| -80% | -$1.23M | ﹤0.01% | 4289 |
|
|
2021
Q2 | $1.57M | Sell |
3,062
-3,438
| -53% | -$2.18M | ﹤0.01% | 3172 |
|
|
2021
Q1 | $5.08M | Buy |
6,500
+1,905
| +41% | +$1.3M | ﹤0.01% | 1833 |
|
|
2020
Q4 | $2.5M | Sell |
4,595
-475
| -9% | -$249K | ﹤0.01% | 2411 |
|
|
2020
Q3 | $2.32M | Sell |
5,070
-5,338
| -51% | -$3.1M | ﹤0.01% | 2298 |
|
|
2020
Q2 | $6.41M | Sell |
10,408
-3,417
| -25% | -$1.89M | 0.01% | 1478 |
|
|
2020
Q1 | $6.57M | Buy |
13,825
+6,854
| +98% | +$3.72M | 0.01% | 1252 |
|
|
2019
Q4 | $4.04M | Buy |
6,971
+3,340
| +92% | +$2.34M | ﹤0.01% | 1903 |
|
|
2019
Q3 | $2.39M | Buy |
3,631
+2,419
| +200% | +$2.01M | ﹤0.01% | 2226 |
|
|
2019
Q2 | $938K | Buy |
+1,212
| New | +$852K | ﹤0.01% | 2709 |
|
|
2018
Q4 | – | Sell |
-1,260
| Closed | -$1.09M | – | 4043 |
|
|
2018
Q3 | $1.09M | Buy |
+1,260
| New | +$910K | ﹤0.01% | 2651 |
|
|
2018
Q1 | – | Sell |
-287
| Closed | -$127K | – | 3829 |
|
|
2017
Q4 | $127K | Sell |
287
-61
| -18% | -$27.8K | ﹤0.01% | 3479 |
|
|
2017
Q3 | $172K | Sell |
348
-211
| -38% | -$106K | ﹤0.01% | 3327 |
|
|
2017
Q2 | $310K | Sell |
559
-144
| -20% | -$91.4K | ﹤0.01% | 3019 |
|
|
2017
Q1 | $465K | Sell |
703
-390
| -36% | -$208K | ﹤0.01% | 2763 |
|
|
2016
Q4 | $365K | Buy |
+1,093
| New | +$351K | ﹤0.01% | 3029 |
|
|
2016
Q3 | – | Sell |
-521
| Closed | -$90K | – | 3591 |
|
|
2016
Q2 | $90K | Sell |
521
-157
| -23% | -$34.2K | ﹤0.01% | 3264 |
|
|
2016
Q1 | $152K | Sell |
678
-2,561
| -79% | -$765K | ﹤0.01% | 3234 |
|
|
2015
Q4 | $1.97M | Sell |
3,239
-1,460
| -31% | -$802K | ﹤0.01% | 2143 |
|
|
2015
Q3 | $2.42M | Buy |
4,699
+4,141
| +742% | +$2.77M | ﹤0.01% | 1945 |
|
|
2015
Q2 | $244K | Buy |
558
+13
| +2% | +$5.02K | ﹤0.01% | 3499 |
|
|
2015
Q1 | $197K | Buy |
545
+130
| +31% | +$49.2K | ﹤0.01% | 3452 |
|
|
2014
Q4 | $149K | Buy |
+415
| New | +$134K | ﹤0.01% | 3860 |
|
Other funds holding TVRD
DGI
C
FCM
D.E. Shaw & Co's TVRD Position: Q2 2024 in Review
D.E. Shaw & Co sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 3,921 shares — an estimated $128K sold.
D.E. Shaw & Co first reported a position in TVRD in Q4 2014 and held it in 29 quarters. The position peaked at $6.57M in Q1 2020. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.
- D.E. Shaw & Co reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
- D.E. Shaw & Co sold 3,921 Tvardi Therapeutics shares in Q2 2024, an estimated $128K.
- D.E. Shaw & Co first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 29 quarters.
- D.E. Shaw & Co's Tvardi Therapeutics position peaked at $6.57M in Q1 2020.
- 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.
Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.